ENTPD1 and neoplasm: Future investigations should explore the temporal coordination between CD39/CD73 induction and TM-PAP inhibition during hypoxic–reoxygenation cycles, considering tumour-specific differences in baseline ectoenzyme expression, phosphate handling, immune composition, and hypoxia dynamics.